Patients’ Preferences for Connected Insulin Pens: A Discrete Choice Experiment Among Patients with Type 1 and Type 2 Diabetes

Seo, Jaein; Heidenreich, Sebastian; Aldalooj, Esraa; Poon, Jiat Ling; Spaepen, Erik; Eby, E.; Newson, Rachel S.

doi:10.1007/s40271-022-00610-x

Cited by 8 publications

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

The use of technology in type 2 diabetes and prediabetes: a narrative review

Liarakos,

Lim,

Leelarathna

et al. 2024

Diabetologia

View full text Add to dashboard Cite

The increasing incidence of type 2 diabetes, which represents 90% of diabetes cases globally, is a major public health concern. Improved glucose management reduces the risk of vascular complications and mortality; however, only a small proportion of the type 2 diabetes population have blood glucose levels within the recommended treatment targets. In recent years, diabetes technologies have revolutionised the care of people with type 1 diabetes, and it is becoming increasingly evident that people with type 2 diabetes can also benefit from these advances. In this review, we describe the current knowledge regarding the role of technologies for people living with type 2 diabetes and the evidence supporting their use in clinical practice. We conclude that continuous glucose monitoring systems deliver glycaemic benefits for individuals with type 2 diabetes, whether treated with insulin or non-insulin therapy; further data are required to evaluate the role of these systems in those with prediabetes (defined as impaired glucose tolerance and/or impaired fasting glucose and/or HbA1c levels between 39 mmol/mol [5.7%] and 47 mmol/mol [6.4%]). The use of insulin pumps seems to be safe and effective in people with type 2 diabetes, especially in those with an HbA1c significantly above target. Initial results from studies exploring the impact of closed-loop systems in type 2 diabetes are promising. We discuss directions for future research to fully understand the potential benefits of integrating evidence-based technology into care for people living with type 2 diabetes and prediabetes. Graphical Abstract

show abstract

The use of technology in type 2 diabetes and prediabetes: a narrative review

Liarakos,

Lim,

Leelarathna

et al. 2024

Diabetologia

View full text Add to dashboard Cite

show abstract

Physician Perceptions of Dose Escalation for Type 2 Diabetes Medications in the United States

Boye,

Jordan,

Malik

et al. 2023

Diabetes Ther

View full text Add to dashboard Cite

Introduction Medications used to treat type 2 diabetes (T2D) often require dose escalation to optimize effectiveness. Physician and patient perceptions of treatment characteristics of T2D medications have previously been examined, but little is known about perceptions of escalation to the optimal dose for each patient. This study examined physicians’ perceptions of dose escalation for medications used to treat T2D. Methods Data on dose escalation and other factors influencing decision-making for treatment of T2D were collected via an online survey of endocrinologists and primary care physicians in the USA. Results The sample included 501 physicians (348 primary care physicians and 153 endocrinologists). Dose escalation was not frequently considered by physicians as a primary factor keeping patients’ from reaching treatment goals (mentioned as a factor by only 7.6% of the sample) or a barrier to prescribing T2D medication (16.2%). Factors more likely to keep patients from reaching treatment goals included an unhealthy diet (86.6%) and medication adherence (77.4%). The most common reasons that physicians reported for escalating dose levels were the need for better glycemic control (reported by 89.8% of the sample), ability to decrease the total number of medications by increasing the dose of one medication (39.9%), and the need for the patient to lose weight (39.3%). Data reported by primary care physicians and endocrinologists followed similar patterns. Conclusions Although common with T2D treatments, escalating the dose of T2D medication was not perceived by physicians to be a significant barrier to attaining treatment goals or prescribing medication. Multiple factors contribute to the decision to escalate the dose of T2D medication.

show abstract

Eliciting Older Cancer Patients’ Preferences for Follow-Up Care to Inform a Primary Healthcare Follow-Up Model in China: A Discrete Choice Experiment

Geng,

Li,

Wang

et al. 2024

Patient

View full text Add to dashboard Cite

Background and Objectives Increasing longevity and advances in treatment have increased the cancer burden in the elderly, resulting in complex follow-up care needs; however, in China, little is known about the follow-up care preferences of these patients. This study quantified older cancer patients’ preferences for follow-up care and examined the trade-offs they are willing to make to accept an alternative follow-up model. Methods A discrete choice experiment was conducted among inpatients aged over 60 years with breast, prostate, or colorectal cancer, at two large tertiary hospitals in Nantong, China. Preference weights for follow-up care were estimated using mixed logit analysis. Subgroup analysis and latent class analysis were used to explore preference heterogeneity. Results Complete results were obtained from 422 patients (144 with breast cancer, 133 with prostate cancer, 145 with colorectal cancer), with a mean age of 70.81 years. Older cancer patients stated a preference for follow-up by specialists over primary healthcare (PHC) providers ( = −1.18, 95% confidence interval −1.40 to −0.97). The provider of follow-up care services was the most valued attribute among patients with breast cancer (relative importance [RI] 37.17%), while remote contact services were prioritized by patients with prostate (RI 43.50%) and colorectal cancer (RI 33.01%). The uptake rate of an alternative care model integrating PHC increased compared with the baseline setting when patients were provided with preferred services (continuity of care, individualized care plans, and remote contact services). Conclusion To encourage older cancer patients to use PHC-integrated follow-up care, alternative follow-up care models need to be based on patients’ preferences before introducing them as a routine option. Supplementary Information The online version contains supplementary material available at 10.1007/s40271-024-00697-4.

show abstract

Patients’ Preferences for Connected Insulin Pens: A Discrete Choice Experiment Among Patients with Type 1 and Type 2 Diabetes

Cited by 8 publications

References 48 publications

The use of technology in type 2 diabetes and prediabetes: a narrative review

The use of technology in type 2 diabetes and prediabetes: a narrative review

Physician Perceptions of Dose Escalation for Type 2 Diabetes Medications in the United States

Eliciting Older Cancer Patients’ Preferences for Follow-Up Care to Inform a Primary Healthcare Follow-Up Model in China: A Discrete Choice Experiment

Contact Info

Product

Resources

About